Clinical Trials Sponsored by Kagawa University

Total 222834 results

Merck KGaA, Darmstadt, Germany

Completed

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (CHANCE)

Squamous Cell Carcinoma of the Head and Neck

China
Merck KGaA, Darmstadt, Germany

Completed

Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit

Hypothyroidism

China
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period (NEO)

Multiple Sclerosis

Taiwan
Merck KGaA, Darmstadt, Germany

Terminated

RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization (RESTORE)

Plaque Psoriasis

Canada
Merck KGaA, Darmstadt, Germany

Completed

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Head and Neck Cancer

Korea, Republic of
Merck KGaA, Darmstadt, Germany

Completed

Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency

Growth Hormone Deficiency

France
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients (Lodoz OS)

Hypertension

Thailand
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study of Gonal-F Filled by Mass Pens in Multifollicular Stimulation Prior to In-vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI)

Multifollicular Stimulation

Korea, Republic of
Merck KGaA, Darmstadt, Germany

Completed

A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)

Infertility

China
Merck KGaA, Darmstadt, Germany

Completed

Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis (AIMS)

Multiple Sclerosis

United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Head and Neck Cancer

France, Russian Federation, Spain, United Kingdom, Germany, Hungary, Poland, Ukraine, Austria, Netherlands, Slovakia, Sweden, Switzerland, Belgium, Italy, Portugal, Czech Republic
Merck KGaA, Darmstadt, Germany

Completed

A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α (P450)

Ovulation Induction

Spain
Merck KGaA, Darmstadt, Germany

Completed

A Non-interventional Study to Identify the Patients With Severe Luteinizing Hormone Deficiency in the Daily Practice

Infertility

Germany
Merck KGaA, Darmstadt, Germany

Withdrawn

A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization (SIGMART)

Angina Pectoris
Merck KGaA, Darmstadt, Germany

Completed

A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring Surgery

Knee Osteoarthritis

Germany, Croatia, Bulgaria, Canada, Finland, Poland, Serbia, South Africa, Sweden
Merck KGaA, Darmstadt, Germany

Terminated

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

France
Merck KGaA, Darmstadt, Germany

Completed

A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment

Metastatic Colorectal Cancer

Taiwan
Merck KGaA, Darmstadt, Germany

Completed

Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) (NEXT)

Non-Small Cell Lung Cancer (NSCLC)

Germany
Merck KGaA, Darmstadt, Germany

Completed

Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

Multiple Sclerosis

Korea, Republic of
Merck KGaA, Darmstadt, Germany

Completed

CONSORT Randomized Controlled Trial in Assisted Reproductive Technology

Infertility

Switzerland
Merck KGaA, Darmstadt, Germany

Terminated

ChangE From Any Systemic psoriasiS therapY to Raptiva (EASY)

Chronic Plaque Psoriasis

Canada
Merck KGaA, Darmstadt, Germany

Completed

A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women

Infertility

Canada
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) (MusiClock)

Multiple Sclerosis, Relapsing-Remitting

Poland
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer

Gastric Cancer

Germany
Merck KGaA, Darmstadt, Germany

Completed

Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina

Multiple Sclerosis

Argentina
Johannes Gutenberg University Mainz
Merck KGaA, Darmstadt, Germany

Completed

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy (AveNEC)

Cancer

Germany
Radboud University Medical Center
Merck KGaA, Darmstadt, Germany

Completed

PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE) (PINNACLE)

Non Small Cell Lung Cancer

Netherlands
Sanwa Kagaku Kenkyusho Co., Ltd.
Fuji Yakuhin Co., Ltd.

Completed

Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout (UPWARD)

Diabetic Nephropathy

Japan
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Recruiting

Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Malaria Infection

Kenya, Burkina Faso, Gambia, Zambia
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model

Healthy

Netherlands
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Active, not recruiting

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Urothelial Cancer

United Kingdom
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib

Healthy

Germany
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

GXR RM China BE Study (Darmstadt - Jiangsu)

Healthy

Germany
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)

Healthy

China
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Pergoveris FD and Liquid China BE Study

Healthy

China
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Study of M5049 in Healthy Japanese and Caucasian Participants

Healthy

United Kingdom
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Enpatoran Human Mass Balance and Absolute Bioavailability Study

Healthy

Netherlands
Seoul National University Hospital
Merck KGaA, Darmstadt, Germany

Completed

Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment (AvelumabHCC)

Carcinoma, Hepatocellular

Korea, Republic of
Chungbuk National University Hospital
Merck KGaA, Darmstadt, Germany

Recruiting

Tepotinib in Solid Tumors Harboring MET Alterations

Solid Tumor | MET Amplification | MET Exon 14 Skipping Mutation

Korea, Republic of
University Hospital Schleswig-Holstein
Drägerwerk AG & Co. KGaA

Completed

Automated Control of Mechanical Ventilation During General Anaesthesia (AVAS)

Anesthesia

Austria, Germany
Pfizer
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (AVENANCE)

Urothelial Carcinoma

France
Merck KGaA, Darmstadt, Germany
Pfizer

Approved for marketing

Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

Metastatic Merkel Cell Carcinoma

France
Sanofi
Merck KGaA, Darmstadt, Germany

Completed

A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients

Neoplasm Malignant

Netherlands, France
The University of Hong Kong
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Completed

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Nasopharyngeal Carcinoma | Metastatic Cancer | Recurrent Carcinoma | Non-keratinizing Carinoma

Hong Kong
Johannes Gutenberg University Mainz
Ipsen; Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA...

Active, not recruiting

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

Cancer

Germany
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Recruiting

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Systemic Lupus Erythematosus

United States, Spain, China, Korea, Republic of, Argentina, Bulgaria, Chile, Greece, Japan, Mauritius, Mexico, Moldova, Republic of, Poland, South Africa, Australia, Colombia, Philippines, Serbia
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants

Healthy

Germany
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Study of M5049 in CLE and SLE Participants

Systemic Lupus Erythematosus | Cutaneous Lupus Erythematosus

Spain, Bulgaria, Germany, Moldova, Republic of, North Macedonia, Ukraine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

Renal Cell Carcinoma

Japan
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

Urothelial Carcinoma

Japan

3

Subscribe